Glaukos Corp. (NYSE:GKOS) Director William J. Phd Link sold 30,000 shares of the stock in a transaction on Thursday, November 17th. The stock was sold at an average price of $33.78, for a total value of $1,013,400.00. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link.

Glaukos Corp. (NYSE:GKOS) traded down 1.24% during mid-day trading on Monday, hitting $32.78. The company had a trading volume of 49,552 shares. The stock has a market capitalization of $1.10 billion, a PE ratio of 575.09 and a beta of 1.45. The stock has a 50 day moving average price of $35.03 and a 200-day moving average price of $31.40. Glaukos Corp. has a 1-year low of $14.25 and a 1-year high of $39.82.

Glaukos Corp. (NYSE:GKOS) last announced its quarterly earnings results on Thursday, November 10th. The company reported $0.03 EPS for the quarter, topping the consensus estimate of $0.00 by $0.03. The business had revenue of $29.60 million for the quarter, compared to analysts’ expectations of $27.21 million. Glaukos Corp. had a net margin of 2.07% and a return on equity of 2.05%. The business’s quarterly revenue was up 55.8% compared to the same quarter last year. During the same quarter in the previous year, the company earned ($0.07) EPS. On average, analysts forecast that Glaukos Corp. will post $0.12 earnings per share for the current year.

Insider Buying and Selling by Quarter for Glaukos Corp. (NYSE:GKOS)

A number of equities research analysts recently issued reports on GKOS shares. Stifel Nicolaus reiterated a “hold” rating on shares of Glaukos Corp. in a research report on Tuesday, September 27th. Cantor Fitzgerald reiterated a “buy” rating and issued a $41.00 price objective on shares of Glaukos Corp. in a research report on Sunday, September 25th. Zacks Investment Research upgraded Glaukos Corp. from a “hold” rating to a “strong-buy” rating and set a $44.00 price objective on the stock in a research report on Wednesday, October 5th. Wells Fargo & Co. started coverage on Glaukos Corp. in a research report on Thursday, October 27th. They issued an “outperform” rating on the stock. Finally, Roth Capital increased their price objective on Glaukos Corp. from $36.50 to $41.00 and gave the stock a “buy” rating in a research report on Tuesday, August 2nd. One investment analyst has rated the stock with a hold rating and six have assigned a buy rating to the company. The company currently has an average rating of “Buy” and an average target price of $38.80.

Hedge funds have recently made changes to their positions in the company. Deerfield Management Co. bought a new stake in shares of Glaukos Corp. during the second quarter valued at approximately $28,697,000. Lord Abbett & CO. LLC boosted its stake in shares of Glaukos Corp. by 126.0% in the second quarter. Lord Abbett & CO. LLC now owns 1,440,111 shares of the company’s stock valued at $41,994,000 after buying an additional 802,763 shares during the last quarter. Gilder Gagnon Howe & Co. LLC boosted its stake in shares of Glaukos Corp. by 129.3% in the second quarter. Gilder Gagnon Howe & Co. LLC now owns 1,141,840 shares of the company’s stock valued at $33,296,000 after buying an additional 643,966 shares during the last quarter. Wellington Management Group LLP bought a new stake in shares of Glaukos Corp. during the first quarter valued at approximately $10,352,000. Finally, Capital World Investors boosted its stake in shares of Glaukos Corp. by 32.6% in the second quarter. Capital World Investors now owns 1,706,070 shares of the company’s stock valued at $49,749,000 after buying an additional 419,437 shares during the last quarter. Institutional investors and hedge funds own 73.87% of the company’s stock.

About Glaukos Corp.

Glaukos Corporation (Glaukos) is an ophthalmic medical technology company. The Company focuses on the development and commercialization of products and procedures for the treatment of glaucoma. Glaukos has developed the micro-invasive glaucoma surgery (MIGS) for glaucoma treatment. It offers iStent, an MIGS device measuring approximately one millimeter long and approximately 0.33 millimeter wide.

5 Day Chart for NYSE:GKOS

Receive News & Stock Ratings for Glaukos Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Glaukos Corp. and related stocks with our FREE daily email newsletter.